HOTLINE 24/7/365 UK: +44 (0) 1483 212150

GMP Expertise

The quality of the medicines, cosmetics, vaccines, biologics and other products produced by a Company, throughout the entire process, from the post-marketing, pre-clinical and clinical phases is paramount to its success.

Regulatory Agencies have zero tolerance to product defects as a result of poor quality.  The expectation is for products to reach the highest standards of purity and conformance to specification. This requires accurate and thorough testing of all materials used to produce the final finished form of the product.

During the clinical trial phase, the final ‘post-marketing production batch size’ may not have been finalised.  The scaling up of the batch sizes can potentially result in quality issues.  The processes involved have to be considered and documented fully in terms of what was done to test the stability of the product quality during production, no matter what the batch size.

PharSafer® partners with experienced GMP and GLP Companies in this area.  They all have the key experience and audit skills for potential Regulatory Inspections, meaning that they can carry out audits of manufacturing sites to ensure they are suitable and prepared for a Regulatory Inspection.

PharSafer® Tweets

Adverse events are overlooked and under-reported. As we head towards the turn of a decade and, almost certainly, a… t.co/yVkzPuJnjQ

Read on Twitter...

Information accessibility to risks associated with drugs is one of the major obstacles preventing patients from rec… t.co/L2feFXDN1X

Read on Twitter...

We have released our latest announcement, regarding the upcoming changes to EU Medical Device Legislation. For mo… t.co/S20M8bbiVb

Read on Twitter...